TAmiRNA

TAmiRNA is a Vienna-based diagnostics company leveraging microRNA and transcriptomic signatures to develop precision medicine tools. Its core business combines a portfolio of Research-Use-Only (RUO) and In-Vitro Diagnostic (IVD) kits for specific disease areas with a robust contract research services arm. The company targets complex conditions like liver disease, osteoporosis, cardiovascular risk, and senescence, utilizing AI-driven analysis to translate RNA biomarkers into actionable diagnostics. With over a decade of expertise, TAmiRNA operates at the intersection of biomarker discovery, validation, and commercial diagnostic service provision.

Platform for discovery and validation of cell-free RNA biomarkers (microRNAs, mRNAs, lncRNAs) from biofluids. Integrates optimized RNA extraction, RT-qPCR/NGS analysis, proprietary miRNA signature panels, synthetic miRNA controls (miND® spike-ins), and AI-driven data analysis.

TAmiRNA competes in the niche of miRNA-based diagnostics and services. Competitors include other specialized miRNA diagnostic firms (e.g., MiRXES, DiamiR), larger liquid biopsy companies expanding into other biomarkers (e.g., Guardant Health, Freenome), and numerous service providers offering RNA sequencing. Its differentiation lies in its deep, specific expertise in cell-free miRNA analysis from challenging samples and its portfolio of pre-validated, disease-specific signature panels.